Zhongzhi Pharmaceutical Holdings (HKSE:03737) Moat Score: 0/10 (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03737 Zhongzhi Pharmaceutical Holdings Ltd HKSE:03737
47 GF Score
Price HK$0.71
GF Value HK$0.89
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Zhongzhi Pharmaceutical Holdings Moat Score?

Zhongzhi Pharmaceutical Holdings has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Zhongzhi Pharmaceutical Holdings has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Zhongzhi Pharmaceutical Holdings might have No Moat - No discernible moat.

Zhongzhi Pharmaceutical Holdings  (HKSE:03737) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Zhongzhi Pharmaceutical Holdings Moat Score Related Terms

HKSE:03737
47GF Score
Zhongzhi Pharmaceutical Holdings Ltd HKSE:03737
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zhongzhi Pharmaceutical Holdings (HKSE:03737) Overvalued in 2026?

Based on GuruFocus' analysis, Zhongzhi Pharmaceutical Holdings stock appears to be undervalued. The current stock price of HK$0.71 is trading 20.2% below its estimated GF Value™ of HK$0.89. GuruFocus considers Zhongzhi Pharmaceutical Holdings to be Modestly Undervalued.

Key valuation signals for HKSE:03737:

  • Moat Score: 0
  • GF Value™: HK$0.89 vs. price of HK$0.71 (20.2% below fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the HKSE:03737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhongzhi Pharmaceutical Holdings Business Description

Address No. 3 Kangtai Road South, Torch Development Zone, Guangdong Province, Zhongshan, CHN
Zhongzhi Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceutical products in the PRC. The Group is a large industrial and trading enterprise group featuring researching, producing, and selling traditional Chinese medicine preparations, prepared slices of Chinese crude drugs, and foods. Its products include Shenqi Koufuye, Yinhuang Jiaonang, Yinhuang Keli, and others. Its segments are the pharmaceutical manufacturing segment, which generates maximum revenue, is engaged in the research and development, manufacturing, and sale of Chinese patent medicines and decoction pieces consisting of traditional decoction pieces and modern decoction pieces, and the operation of the chain pharmacies segment.
47GF Score

Get the complete analysis for HKSE:03737

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.71
Price
HK$0.89
GF Value